Fujifilm : to terminate the enrollment of subjects in the phase III clinical trial of anti-influenza drug Avigan® Tablet in Japan, targeting COVID-19 patients (Fujifilm)
TOKYO, March 11, 2022-FUJIFILM Toyama Chemical Co., Ltd. announces a pause in enrollment, as of the end of March, in the currently ongoing phase III clinical trial in Japan concerning... | March 11, 2022
Chuo Ku Junji Okada Head Office Toyama Chemical Co Ltd Fujifilm Holdings Corporation Stock Exchange Press Release
Source: marketscreener.com